ライフサイエンスコーパス: blood product transfusion

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 risk of reoperation for bleeding or need for blood product transfusion.

2 tients (69%), and 28 patients (67%) required blood product transfusion.

3 ed growth factor support, and three required blood product transfusions.

4 , continuous veno-venous hemofiltration, and blood product transfusions.

5 nt has reduced intraoperative blood loss and blood product transfusions.

6 iated with major blood loss and the need for blood product transfusions.

7 2% vs. 2.4%, p = 0.002), had higher rates of blood product transfusions (13.1% vs. 3.1%, p < 0.0001),

8 ump CABG, significantly reduced the rates of blood-product transfusion (50.7% vs. 63.3%; relative ris

9 4%; P=0.96) or requirement for postoperative blood product transfusion (adjusted OR, 1.17; 95% CI, 0.

10 irus infection that presumably resulted from blood product transfusions administered before the intro

11 s is likely related to the administration of blood product transfusion after the onset of fulminant h

12 ndrome continues to be supportive care, with blood product transfusion and antibiotics for infectious

13 nal shock, maternal requirement of allogenic blood product transfusion and lower gestational age were

14 and related physician orders, demographics, blood products transfusion, and outcomes were collected

15 ntly, Jehovah's Witness patients, who refuse blood product transfusion, are usually excluded from liv

16 Sedation, blood product transfusions as indicated, antibiotics, an

17 seropositive, and who received more than 20 blood product transfusions before BMT.

18 ostatic reoperation and the requirements for blood product transfusions during and after off-pump cor

19 et count), and its use may avoid unnecessary blood product transfusion in patients with cirrhosis and

20 Timely LDLT can be done successfully without blood product transfusion in selected patients.

21 Red blood cell and blood product transfusion in the fetus, neonate, and pre

22 Prehospital blood product transfusion in trauma care remains controv

23 rs such as total parenteral nutrition (TPN), blood product transfusions, invasive procedures, central

24 tality (odds ratio, 0.40; P=0.017), need for blood product transfusion (odds ratio, 0.74; P=0.009), m

25 to treat, 22.6), but had no effect on other blood product transfusions or major complications.

26 Restrictive blood product transfusion practices following congenital

27 military combat causalities in Afghanistan, blood product transfusion prehospital or within minutes

28 n the incidence of hemostatic reexploration, blood product transfusion rates, morbidity, and mortalit

29 Early postoperative chest-tube output, blood-product transfusion requirements, and levels of se

30 ocol, all subjects in the SOC group received blood product transfusions versus 5 in the TEG group (10

31 No significant clinical bleeding events or blood product transfusions were observed in this trial.

32 Pugh B: 26; C: 58) without overt bleeding or blood-product transfusion were prospectively evaluated w

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。